Forma Therapeutics Holdings (FMTX) Reports In-Line Q1 EPS

Go back to Forma Therapeutics Holdings (FMTX) Reports In-Line Q1 EPS

Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 14, 2021 7:05 AM EDT

Development pipeline progressing to key upcoming clinical milestones

Multiple-ascending dose (MAD) cohorts of FT-4202 Phase 1 trial in sickle cell disease completed; hemoglobin increased 1 g/dL in approximately 71% of patients and improved hematologic and hemolytic markers consistent with improved red blood cell (RBC) health

Updated MAD results and initial open-label extension trial (OLE) results to date to be presented at European Hematology Association (EHA) Virtual Congress in June

Phase 1 trial of FT-7051 in metastatic castration-resistant prostate cancer (mCRPC) ongoing, initial results expected fourth quarter of... More